产品详情
Targets
Target | Value |
---|---|
RET | IC50: 1.5nM |
Raf-1 | IC50: 2.5nM |
VEGFR2 | IC50: 4.2nM |
Kit | IC50: 7nM |
VEGFR1 | IC50: 13nM |
B-Raf(V600E) | IC50: 19nM |
PDGFRβ | IC50: 22nM |
B-Raf | IC50: 28nM |
VEGFR3 | IC50: 46nM |
FGFR1 | IC50: 202nM |
Tie-2 | IC50: 311nM |
In vitro (25°C) | DMSO | 88 mg/mL (182.26 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 2% DMSO+30% PEG 300+5% Tween 80+ddH2O | 4 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 20.71 mL | 103.56 mL | 207.13 mL |
0.5 mM | 4.14 mL | 20.71 mL | 41.43 mL |
1 mM | 2.07 mL | 10.36 mL | 20.71 mL |
5 mM | 0.41 mL | 2.07 mL | 4.14 mL |
*The above data is based on the productmolecular weight 482.8. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
目录号 | A10250 |
---|---|
作用机制 | Inhibitor (抑制剂) |
M. Wt | 482.8 |
Formula | C21H15ClF4N4O3 |
Purity | >99% |
Storage | Store lyophilized at -20ºC, keep desiccated. |
CAS No. | 755037-03-7 |
SMILES | CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F |
产品资料
产品标签
Product Questions
Product Questions
Brivanib (BMS-540215)
Brivanib (BMS-540215)是一种VEGFR-2抑制剂,IC50为25 nM,Ki为26 nM。
Sunitinib Malate
Sunitinib Malate是一种多靶点RTK抑制剂,作用于VEGFR2 (Flk-1)和 PDGFRβ,也会抑制c-Kit的活性。用于治疗肾细胞癌…
E-7050 (Golvatinib)
E-7050 (Golvatinib)是具有潜在抗肿瘤活性的c-Met(肝细胞生长因子受体)和VEGFR-2(血管内皮生长因子受体-2)酪氨酸…
NVP-BAW2881
NVP-BAW2881是有效的选择性VEGFR抑制剂(血管内皮生长因子受体酪氨酸激酶抑制剂),IC50 为值9 nM,具有抑制…
PLX4032 (Vemurafenib)
PLX4032(Vemurafenib)也称为RG7204,Vemurafenib,R7204,RO5185426。PLX4032是B-raf抑制剂,IC50为44 nM。
Pazopanib (GW-786034)
Pazopanib (GW-786034)是VEGFR-1,VEGFR-2,VEGFR-3,PDGFR-a/β和c-kit的有效且选择性的多靶点酪氨酸激酶抑制剂,可阻…